CFA
IRMD icon

Camarda Financial Advisors’s iRadimed IRMD Stock Holding History

Camarda Financial Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.79M Buy
28,990
+116
+0.4% +$11.6K 1.47% 29
2025
Q4 		$2.81M Buy
+28,874
New +$2.48M 1.07% 31

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Camarda Financial Advisors's IRMD Position: Q1 2026 in Review

Camarda Financial Advisors increased its iRadimed (IRMD) stake by 0.4% in Q1 2026, buying an estimated $11.6K and bringing the position to 28,990 shares worth $2.79M. The position accounts for 1.47% of the portfolio, ranked #29.

Camarda Financial Advisors first reported a position in IRMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.81M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Camarda Financial Advisors held 28,990 shares of iRadimed worth $2.79M as of Q1 2026.
  • Camarda Financial Advisors bought 116 iRadimed shares in Q1 2026, an estimated $11.6K.
  • iRadimed made up 1.47% of Camarda Financial Advisors's portfolio in Q1 2026, its #29 holding.
  • Camarda Financial Advisors first reported a position in iRadimed in Q4 2025 and has held it in 2 quarters since.
  • Camarda Financial Advisors's iRadimed position peaked at $2.81M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Camarda Financial Advisors's 13F filing for Q1 2026, filed 14 May 2026.